AFP and hepatocellular carcinoma: In this work we describe a novel physic-mathematical model that allowed us to investigate the biological mechanisms of response to TKI in advanced HCC with elevation of AFP and PIVKA-II levels, two of the most studied and validated serological biomarkers already used in clinical practice [20].